Toggle navigation
About The Disease
Elly’s Team
Letter To Community
Media
Contact Us
Donate
Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after Diagnosis
Genezen Partners with Elly’s Team on Development for AAV Serotype 9 Gene Replacement Therapy for NEDAMSS; Genezen CTO Dr. Susan D’Costa to join nonprofit’s board
